<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383447</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2010-02202</org_study_id>
    <secondary_id>J1023</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT01383447</nct_id>
  </id_info>
  <brief_title>Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of entinostat when given&#xD;
      together with imatinib mesylate and to see how well it works in treating patients with&#xD;
      relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.&#xD;
      Entinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the&#xD;
      enzymes needed for cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of entinostat when given in combination with&#xD;
      imatinib (matinib mesylate).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the rate of complete response (CR) for patients greater ≥ 18 years of age with&#xD;
      relapsed/refractory Ph+ ALL treated with a combination of entinostat and imatinib.&#xD;
&#xD;
      II. To estimate the 1 year progression free survival (PFS) for patients greater ≥ 18 years of&#xD;
      age with relapsed/refractory Ph+ ALL treated with a combination of entinostat and imatinib&#xD;
      III. To describe the comparative pharmacokinetics (PK) and pharmacodynamics (PD) of&#xD;
      entinostat when administered alone vs. in combination with imatinib.&#xD;
&#xD;
      IV. To assess the predictive value of levels of flow cytometric minimal residual disease&#xD;
      (MRD) on duration of progression free survival for the study population.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of entinostat followed by a phase II study.&#xD;
&#xD;
      Patients receive entinostat orally (PO) daily on days 1, 8, 15, and 22 and imatinib mesylate&#xD;
      PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was halted prematurely by the NCI for low accrual.&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
    <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</measure>
    <time_frame>Day 4 and 11</time_frame>
    <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student's t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher's exact tests or Wilcoxon rank sum tests as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</measure>
    <time_frame>Day 29</time_frame>
    <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>HDAC inhibitor SNDX-275</other_name>
    <other_name>SNDX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
    <other_name>HPLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat and imatinib mesylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed BCR-ABL1 associated (Ph+) acute&#xD;
             lymphoblastic leukemia (ALL) with primary refractory or relapsed disease;&#xD;
             demonstration of BCR-ABL1 in leukemia cells by one or more of the following is&#xD;
             required: t(9;22)(q34;q11.2) cytogenetics; FISH for BCR-ABL1 fusion; RT-PCR for&#xD;
             BCR-ABL1 fusion&#xD;
&#xD;
          -  Prior treatment with tyrosine kinase inhibitors (including imatinib, nilotinib and/or&#xD;
             dasatinib) is allowed, although patients must be off any tyrosine kinase inhibitor for&#xD;
             a minimum of 72 hours prior to beginning protocol therapy&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          -  Total WBC =&lt; 150,000 with no evidence for ongoing or impending leukostasis&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.0 mg/dL unless elevated due to Gilbert's, hemolysis or leukemic&#xD;
             infiltration&#xD;
&#xD;
          -  Aspartate transaminase (AST)/alanine transaminase (ALT) =&lt; 2.5 × upper limit of normal&#xD;
             (ULN) unless due to leukemic infiltration&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL or creatinine clearance &gt; 50 ml/min&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 45% as measured by echocardiogram (ECHO)&#xD;
             or MUGA&#xD;
&#xD;
          -  Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic,&#xD;
             are eligible provided that they are &gt; 4 weeks from stem cell infusion, have no active&#xD;
             GVHD, and meet other eligibility criteria&#xD;
&#xD;
          -  Patients who fail primary induction therapy or relapse after achieving complete&#xD;
             remission (CR) are eligible if they are &gt; 3 weeks off cytotoxic chemotherapy and &gt; 2&#xD;
             weeks off radiation therapy; patients must be off biologic therapies including&#xD;
             hematopoietic growth factors &gt; 1 week; if using hydroxyurea (HU), steroids, or other&#xD;
             non-cytotoxics for blast count control, patient must be off for &gt; 24 hrs before&#xD;
             starting protocol therapy; patients must have recovered from all acute toxicities from&#xD;
             any previous therapy&#xD;
&#xD;
          -  Female patients of childbearing age must have negative pregnancy test; women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for the duration&#xD;
             of study participation; should a woman become pregnant or suspect she is pregnant&#xD;
             while participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Active CNS leukemia; patients with known previous CNS leukemia may continue to receive&#xD;
             intrathecal therapy with ara-C, methotrexate, and/or thiotepa plus steroids as&#xD;
             prophylaxis against reactivation of previous CNS disease&#xD;
&#xD;
          -  Patients may not have received previous treatment with entinostat or other HDAC&#xD;
             inhibitors&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to entinostat or other agents used in study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             untreated infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with entinostat&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</title>
        <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Entinostat When Given in Combination With Imatinib Mesylate</title>
          <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</title>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Response (CR) for Adults With Relapsed/Refractory Ph+ ALL Treated With a Combination of Entinostat (at the Dose Determined in Phase 1) and Imatinib Mesylate</title>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</title>
        <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
        <time_frame>At 1 year</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for Adults With Relapsed/Refractory Ph+ ALL Treated With Combination of Entinostat and Imatinib Mesylate</title>
          <description>The Kaplan-Meier estimator will be used to estimate PFS with a 95% confidence interval from study entry.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</title>
        <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student's t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher's exact tests or Wilcoxon rank sum tests as appropriate.</description>
        <time_frame>Day 4 and 11</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of Entinostat Alone vs. Entinostat Plus Imatinib Mesylate</title>
          <description>Entinostat concentrations will be compared when administered alone or in combination with imatinib by paired Student's t test (day 4 vs 11 concentrations) or Wilcoxon signed rank tests as appropriate. Association between exposure parameters and PD endpoints (e.g., apoptosis, histone acetylation, BCR-ABL expression) will be assessed using Fisher's exact tests or Wilcoxon rank sum tests as appropriate.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</title>
        <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
        <time_frame>Day 29</time_frame>
        <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Entinostat and Imatinib Mesylate)</title>
            <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Predictive Values of Levels of Flow Cytometric Minimal Residual Disease (MRD) on Duration of Progression Free Survival for the Study Population</title>
          <description>Kaplan-Meier PFS curves and cumulative incidence of progression curves will be generated for patients above vs. below each threshold, and log rank will be used to compare the curves.</description>
          <population>This study was halted prematurely by the NCI for low accrual. No results were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Entinostat and Imatinib Mesylate)</title>
          <description>Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
entinostat: Given PO&#xD;
imatinib mesylate: Given PO&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
pharmacological study: Correlative studies&#xD;
western blotting: Correlative studies&#xD;
immunohistochemistry staining method: Correlative studies&#xD;
flow cytometry: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
high performance liquid chromatography: Correlative studies&#xD;
mass spectrometry: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain: bone marrow site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Brown</name_or_title>
      <organization>Johns Hopkins Sidney Kimmel Cancer Center</organization>
      <phone>410-614-4915</phone>
      <email>pbrown2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

